ATE458754T1 - Screening-verfahren, verfahren zur aufreinigung nichtdiffundierbarer a-beta-oligomere, selektive antikörper gegen diese nichtdiffundierbaren a- beta-oligomere und verfahren zur herstellung dieser antikörper - Google Patents

Screening-verfahren, verfahren zur aufreinigung nichtdiffundierbarer a-beta-oligomere, selektive antikörper gegen diese nichtdiffundierbaren a- beta-oligomere und verfahren zur herstellung dieser antikörper

Info

Publication number
ATE458754T1
ATE458754T1 AT06707413T AT06707413T ATE458754T1 AT E458754 T1 ATE458754 T1 AT E458754T1 AT 06707413 T AT06707413 T AT 06707413T AT 06707413 T AT06707413 T AT 06707413T AT E458754 T1 ATE458754 T1 AT E458754T1
Authority
AT
Austria
Prior art keywords
diffusable
antibodies
beta oligomers
globulomers
derivatives
Prior art date
Application number
AT06707413T
Other languages
English (en)
Inventor
Heinz Hillen
Andreas Striebinger
Patrick Keller
Stefan Barghorn
Ulrich Ebert
Original Assignee
Abbott Gmbh & Co Kg
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=36581967&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE458754(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Abbott Gmbh & Co Kg filed Critical Abbott Gmbh & Co Kg
Application granted granted Critical
Publication of ATE458754T1 publication Critical patent/ATE458754T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4711—Alzheimer's disease; Amyloid plaque core protein
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Neurology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Urology & Nephrology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Hematology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Neurosurgery (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Psychiatry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cell Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Food Science & Technology (AREA)
  • Hospice & Palliative Care (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Epidemiology (AREA)
AT06707413T 2005-03-05 2006-03-03 Screening-verfahren, verfahren zur aufreinigung nichtdiffundierbarer a-beta-oligomere, selektive antikörper gegen diese nichtdiffundierbaren a- beta-oligomere und verfahren zur herstellung dieser antikörper ATE458754T1 (de)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP05004858 2005-03-05
US66447705P 2005-03-23 2005-03-23
EP05006568 2005-03-24
US74086605P 2005-11-30 2005-11-30
PCT/EP2006/001984 WO2006094724A2 (en) 2005-03-05 2006-03-03 Screening method, process for purifying of non-diffusible a-beta oligomers, selective antibodies against said non-diffusible a-beta oligomers and a process for manufacturing of said antibodies

Publications (1)

Publication Number Publication Date
ATE458754T1 true ATE458754T1 (de) 2010-03-15

Family

ID=36581967

Family Applications (1)

Application Number Title Priority Date Filing Date
AT06707413T ATE458754T1 (de) 2005-03-05 2006-03-03 Screening-verfahren, verfahren zur aufreinigung nichtdiffundierbarer a-beta-oligomere, selektive antikörper gegen diese nichtdiffundierbaren a- beta-oligomere und verfahren zur herstellung dieser antikörper

Country Status (14)

Country Link
US (1) US20090035295A1 (de)
EP (2) EP2204381A1 (de)
KR (1) KR20080021585A (de)
CN (1) CN101365717A (de)
AT (1) ATE458754T1 (de)
AU (1) AU2006222193B2 (de)
BR (1) BRPI0608076A2 (de)
CA (1) CA2599792A1 (de)
DE (1) DE602006012459D1 (de)
ES (1) ES2340414T3 (de)
IL (1) IL185392A0 (de)
MX (1) MX2007010687A (de)
WO (1) WO2006094724A2 (de)
ZA (1) ZA200707234B (de)

Families Citing this family (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002003911A2 (en) 2000-07-07 2002-01-17 Lars Lannfelt Prevention and treatment of alzheimer's disease
DE10303974A1 (de) 2003-01-31 2004-08-05 Abbott Gmbh & Co. Kg Amyloid-β(1-42)-Oligomere, Verfahren zu deren Herstellung und deren Verwendung
SE0401601D0 (sv) 2004-06-21 2004-06-21 Bioarctic Neuroscience Ab Protofibril specific antibodies and uses thereof
EP1928905B1 (de) 2005-09-30 2015-04-15 AbbVie Deutschland GmbH & Co KG Bindungsdomänen von proteinen der repulsive guidance molecule (rgm) proteinfamilie und funktionale fragmente davon sowie deren verwendung
KR101667623B1 (ko) * 2005-11-30 2016-10-19 애브비 인코포레이티드 아밀로이드 베타 단백질에 대한 모노클로날 항체 및 이의 용도
AU2013200177B2 (en) * 2005-11-30 2014-10-02 Abbvie Deutschland Gmbh & Co Kg Monoclonal antibodies against amyloid beta protein and uses thereof
EP2289909B1 (de) 2005-11-30 2014-10-29 AbbVie Inc. Screeningsverfahren, Verfahren zur Reinigung von nicht-diffundierenden Beta-Oligomeren, selektive Antikörper gegen genannten nichtdiffundierende Beta-Oligomere und Verfahren zur Herstellung von genannten Antikörpern
RS53291B (sr) 2005-12-12 2014-08-29 Ac Immune S.A. Beta 1-42 specifična monoklonska antitela sa terapeutskim svojstvima
SI2004688T2 (sl) 2006-03-23 2014-05-30 Bioarctic Neuroscience Ab Izboljšana protofibrilno selektivna protitelesa in njihova uporaba
CL2007002070A1 (es) 2006-07-14 2008-02-08 Ac Immune S A Genentech Inc Anticuerpo quimerico o humanizado, o fragmentos de ellos, que se adhieren especificamente a por lo menos un epitopo en la proteina beta-amiloide; molecula de acido nucleico que lo codifica; composicion que lo comprende; su uso para tratar enfermedade
US8455626B2 (en) 2006-11-30 2013-06-04 Abbott Laboratories Aβ conformer selective anti-aβ globulomer monoclonal antibodies
CA2674140C (en) * 2007-01-05 2018-05-15 University Of Zurich Method of providing disease-specific binding molecules and targets
HRP20140049T1 (hr) 2007-01-05 2014-02-28 University Of Zürich Anti beta-amiloid antitijela i njihova upotreba
DK2104682T3 (en) 2007-01-11 2017-01-16 Michael Bacher DIAGNOSIS AND TREATMENT OF ALZHEIMER'S AND OTHER DEMENTIA DISEASES
EP2486928A1 (de) 2007-02-27 2012-08-15 Abbott GmbH & Co. KG Verfahren zur Behandlung von Amyloidosen
US20090232801A1 (en) * 2007-05-30 2009-09-17 Abbot Laboratories Humanized Antibodies Which Bind To AB (1-42) Globulomer And Uses Thereof
US8613923B2 (en) 2007-06-12 2013-12-24 Ac Immune S.A. Monoclonal antibody
US8048420B2 (en) 2007-06-12 2011-11-01 Ac Immune S.A. Monoclonal antibody
TW201518320A (zh) * 2007-06-12 2015-05-16 Ac Immune Sa 特異性結合β-類澱粉蛋白之抗體及相關核酸分子、表現載體、細胞、組合物、套組、方法及用途
AU2008311367B2 (en) 2007-10-05 2014-11-13 Ac Immune S.A. Use of anti-amyloid beta antibody in ocular diseases
AU2008311366B2 (en) * 2007-10-05 2015-03-12 Ac Immune S.A. Use of anti-amyloid beta antibody in ocular diseases
EP2210901A4 (de) * 2007-10-19 2012-04-25 Immunas Pharma Inc Zur spezifischen bindung an ein oligomer fähiger antikörper, und dessen verwendung
PT2246427T (pt) 2008-02-08 2017-03-03 Immunas Pharma Inc Anticorpos capazes de se ligar especificamente a oligómeros beta amilóides e a sua utilização
US8962803B2 (en) 2008-02-29 2015-02-24 AbbVie Deutschland GmbH & Co. KG Antibodies against the RGM A protein and uses thereof
US20110092445A1 (en) * 2008-07-25 2011-04-21 Abbott Laboratories Amyloid ß peptide analogues, oligomers thereof, processes for preparing and composi-tions comprising said analogues or oligomers, and their uses
WO2010010469A2 (en) * 2008-07-25 2010-01-28 Abbott Gmbh & Co. Kg Abeta (x-38..43) oligomers, and processes, compositions, and uses thereof
US9085614B2 (en) 2008-08-01 2015-07-21 Immunas Pharma, Inc. Antibodies that specifically bind to Aβ oligomers and uses thereof
KR101781228B1 (ko) 2008-12-19 2017-09-22 바이오겐 인터내셔널 뉴로사이언스 게엠베하 인간 항-알파-시누클레인 자가항체
EP2416795B1 (de) 2009-04-09 2015-06-03 Cognition Therapeutics, Inc. Kognitionsabbauhemmer
EP2419447B1 (de) 2009-04-17 2017-08-23 Immunas Pharma, Inc. Spezifisch an abeta-oligmomere bindende antikörper und ihre verwendung
US8512677B2 (en) 2009-04-27 2013-08-20 Case Western Reserve University Pyro-glutamate Aβ targeting agents
EP2458983B1 (de) 2009-07-31 2015-07-08 Cognition Therapeutics, Inc. Hemmer des kognitiven abbaus
DK2462161T3 (en) * 2009-08-06 2017-06-06 Immunas Pharma Inc Antibodies specifically binding to A-beta oligomers and their use
EP2462162B1 (de) 2009-08-06 2016-10-12 Immunas Pharma, Inc. Spezifisch an abeta-oligmomere bindende antikörper und ihre verwendung
BR112012013734A2 (pt) 2009-12-08 2017-01-10 Abbott Gmbh & Co Kg anticorpos monoclonais contra a proteína rgm a para uso no tratamento da degeneração da camada de fibras nervosas da retina.
US20130071330A1 (en) * 2010-02-26 2013-03-21 Susan Catalano Methods of identifying agents effective to treat cognitive decline and diseases associated therewith
EP2558494B1 (de) 2010-04-15 2018-05-23 AbbVie Inc. Amyloid-beta-bindende proteine
CA2806909C (en) 2010-07-30 2019-12-17 Ac Immune S.A. Safe and functional humanized antibodies
MX358739B (es) 2010-08-14 2018-09-03 Abbvie Inc Star Proteinas de union a amiloide beta.
WO2012054333A2 (en) * 2010-10-20 2012-04-26 Merck Sharp & Dohme Corp. Methods for identifying inhibitors of abeta42 oligomers
RU2013140467A (ru) 2011-02-02 2015-03-10 Когнишн Терапьютикс, Инк. Выделенные соединения из масла куркумы и способы применения
US9061006B2 (en) 2011-03-08 2015-06-23 Ramot At Tel-Aviv University Ltd. Compositions and methods for diagnosing and treating phenylketonuria (PKU)
MX357193B (es) 2011-06-23 2018-06-29 Univ Zuerich Moleculas de union anti-alfa sinucleina.
RS57603B1 (sr) 2012-01-27 2018-11-30 Abbvie Deutschland Sastav i metod za dijagnozu i tretiranje bolesti povezanih sa degeneracijom neurita
CA2867338A1 (en) * 2012-03-13 2013-09-19 Janssen Alzheimer Immunotherapy Oligomeric a.beta. in the diagnosis, prognosis, and monitoring of alzheimer's disease
RU2692258C2 (ru) 2014-01-31 2019-06-24 Когнишн Терапьютикс, Инк. Композиции изоиндолина и способы лечения нейродегенеративного заболевания
US9573994B2 (en) 2014-07-10 2017-02-21 Bioarctic Neuroscience Ab Aβ protofibril binding antibodies
MA41115A (fr) 2014-12-02 2017-10-10 Biogen Int Neuroscience Gmbh Procédé de traitement de la maladie d'alzheimer
KR101856838B1 (ko) * 2016-02-17 2018-06-19 이희정 베타-아밀로이드 올리고머에 대한 압타머 및 이의 용도
CN106519029B (zh) * 2016-10-31 2020-03-17 山东泰邦生物制品有限公司 一种Aβ寡聚体抗体的制备工艺
BR112019023851A2 (pt) 2017-05-15 2020-08-18 Cognition Therapeutics, Inc. compostos, suas composições farmacêuticas e métodos para tratamento de doenças neurodegenerativas
CN118370815A (zh) 2017-08-22 2024-07-23 渤健马萨诸塞州股份有限公司 含有抗β淀粉样蛋白抗体的药物组合物
CN109851668B (zh) * 2018-12-26 2022-12-23 广东菲鹏生物有限公司 一种saa蛋白免疫原及其制备方法和抗人血清淀粉样蛋白a多克隆抗体
CN111085011B (zh) * 2019-12-30 2021-12-03 中南民族大学 一种分子印迹磁性纳米材料的制备方法及其在γ-氨基丁酸提纯中的应用
CN117024554A (zh) * 2023-05-30 2023-11-10 中国人民解放军空军军医大学 一种Aβ1-42寡聚体存储液的制备方法及其应用

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5705330A (en) 1995-04-14 1998-01-06 Abbott Laboratories Chemiluminescent immunoassay for antibody detection
US6218506B1 (en) 1997-02-05 2001-04-17 Northwestern University Amyloid β protein (globular assembly and uses thereof)
DE19916417A1 (de) 1999-04-01 2000-10-19 Schering Ag Amyloidspezifisches Aptamer
US20020002270A1 (en) * 1999-06-16 2002-01-03 Raymond P. Zinkowski Purified antigen for alzheimer's disease, and methods of obtaining and using same
AU6524500A (en) 1999-08-04 2001-03-05 Northwestern University Amyloid beta protein (globular assembly and uses thereof)
DE10303974A1 (de) * 2003-01-31 2004-08-05 Abbott Gmbh & Co. Kg Amyloid-β(1-42)-Oligomere, Verfahren zu deren Herstellung und deren Verwendung
US20070015218A1 (en) 2003-10-14 2007-01-18 University Of South Florida A Method for the Separation Anti-Amyloid Beta Antibody with Amyloid Beta Peptide

Also Published As

Publication number Publication date
CA2599792A1 (en) 2006-09-14
AU2006222193B2 (en) 2011-11-17
KR20080021585A (ko) 2008-03-07
ZA200707234B (en) 2011-02-23
WO2006094724A2 (en) 2006-09-14
DE602006012459D1 (de) 2010-04-08
EP2204381A1 (de) 2010-07-07
MX2007010687A (es) 2008-01-28
EP1861422B1 (de) 2010-02-24
BRPI0608076A2 (pt) 2009-11-10
AU2006222193A1 (en) 2006-09-14
US20090035295A1 (en) 2009-02-05
WO2006094724A3 (en) 2007-02-15
CN101365717A (zh) 2009-02-11
ES2340414T3 (es) 2010-06-02
IL185392A0 (en) 2008-02-09
EP1861422A2 (de) 2007-12-05

Similar Documents

Publication Publication Date Title
ATE458754T1 (de) Screening-verfahren, verfahren zur aufreinigung nichtdiffundierbarer a-beta-oligomere, selektive antikörper gegen diese nichtdiffundierbaren a- beta-oligomere und verfahren zur herstellung dieser antikörper
ATE478084T1 (de) Verfahren zur herstellung von 4'- azidocytidinderivaten
MX2009003468A (es) Anticuerpo humanizado contra beta amiloide.
DE602007011171D1 (de) Zusammensetzung und Verfahren zur Herstellung von Steviolglykosiden
ATE306252T1 (de) Verfahren zur herstellung kristalliner partikel zur inhalation
DE60335552D1 (de) Neue zusammensetzung und verfahren zur behandlung von immunerkrankungen
EA200601141A1 (ru) Сульфонамидные производные для лечения заболеваний
ATE548353T1 (de) Verfahren zur herstellung von substituierte n- aryl-n'-ä3-(1h-pyrazol-5-yl)phenylü-harnstoffe and intermediate davon.
DE602005002654D1 (de) Prozess zur Herstellung von Nano- und Mikrokapseln aus Spinnenseidenprotein
CY1107082T1 (el) Μεθοδος καθαρισμου αλβουμινης η οποια περιλαμβανει ενα σταδιο νανοδιηθησης, διαλυμα και συνθεση για θεραπευτικη χρηση που περιεχουν την ιδια
DE60033566D1 (de) Neue sertralinhydrochlorid polymorphe, verfahren zur herstellung und zur verwendung und diese enthaltende zusammensetzungen
EA200501615A1 (ru) (2-гидрокси-2-(4-гидрокси-3-гидроксиметилфенил)этиламино)пропилфенильные производные в качестве бета-2-агонистов
SG149045A1 (en) Novel fused pyrrolocarbazoles
MY149041A (en) Novel fused pyrrolocarbazoles
ATE464338T1 (de) Neuer schaumstoffmodifikator, aus diesem neuen schaumstoffmodifikator hergestellte schaumstoffe und verfahren zur herstellung dieser schaumstoffe
DE502004010130D1 (de) Proteinpulver und daraus erhaltenes proteinhaltiges getränk
ATE432278T1 (de) Verbindungen zur behandlung von krankheiten
ATE407127T1 (de) Verfahren zur herstellung von beraprost und dessen salzen
ATE401300T1 (de) Verfahren zur herstellung von valsartan und vorstufen davon
ATE354583T1 (de) Verfahren zur herstellung c-7 substituierter 5- androstene
ATE442355T1 (de) Herstellung von 4,5-dialkyl-3-acylpyrrol-2- carbonsäurederivaten durch synthese nach fischer- fink und anschliebende acylierung
DE502004001985D1 (de) Verfahren zur Herstellung von expandiertem Graphit
ATE372114T1 (de) Verfahren zur erhöhung des testosteronspiegels
ATE461934T1 (de) Verfahren zur herstellung von 17-hydroxy-6 beta, 7 beta, 15 beta,16 beta-bismethylen-17alpha-pregn-4-en-3-on-21-car onsäure -lacton und schlüsselzwischenprodukte für dieses verfahren
ATE337796T1 (de) Verfahren zur herstellung von hyperpolarisiertem 129xe

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties